Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
NEW YORK, Oct. 28, 2016 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of LifeVantage Corporation (“LifeVantage” or the “Company”) (NASDAQ:LFVN) between November 4, 2015 and September 13, 2016.
You are hereby notified that a securities class action has commenced in the USDC for the District of Utah. If you purchased or otherwise acquired LifeVantage securities between November 4, 2015 and September 13, 2016, your rights may be affected by this action. To get more information go to: http://www.zlk.com/pslra/lifevantage-corporation.
The complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) LifeVantage lacked effective internal financial controls; (2) therefore, the Company had improperly accounted for sales in certain international markets, along with associated revenue and income tax accruals; and (3) consequently, LifeVantage’s public statements were materially false and misleading at all relevant times.
If you suffered a loss in LifeVantage you have until November 14, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://www.zlk.com/pslra/lifevantage-corporation.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
